Development, production and testing of novel glycoconjugate pig vaccines

点击翻译按钮获取中文摘要

Healthily maintained livestock are essential for economic and societal prosperity. We propose to exploit ground-breaking technology to produce low cost glycoconjugate vaccines to protect against three major pig diseases (porcine pleuropneumonia, Glässer's disease and S. suis-induced meningitis), where current vaccines are unsatisfactory. We have developed technology to generate cloned glycoconjugates in E. coli cells that act as mini factories to produce an inexhaustible and renewal supply of pure vaccine. Due to production costs, conventional chemically synthesised glycoconjugate vaccines have not been used for animals, but have an excellent track record in humans, where over a billion doses have been used. Through the LSHTM business development office and industrial collaborators we will develop, produce and test new vaccines against the three major pig respiratory diseases. A new company, ArcVax, will be spun-out to further develop the technology and commercialise vaccine product.